Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands

Cornea

Volumn 31, Issue 11, 2012, Pages 1229-1234

  Arita, Reiko ^a,b   Itoh, Kouzo ^a   Maeda, Shuji ^c   Maeda, Koshi ^c   Furuta, Ayumu ^c   Tomidokoro, Atsuo ^b   Aihara, Makoto ^b   Amano, Shiro ^b  

^a Itoh Clinic   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Maeda Ophthalmic Clinic   (Japan)

Author keywords

antiglaucomatous eye drops; dry eye; meibography; meibomian gland

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; EYE DROPS; LATANOPROST; NIPRADILOL; PILOCARPINE; PRESERVATIVE; PROSTAGLANDIN DERIVATIVE; SOFZIA; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLAUCOMA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEIBOMIAN GLAND; MEIBOMIAN GLAND FUNCTION; MEIBOMIAN GLAND MORPHOLOGY ALTERATION; MEIBOMIAN GLAND MORPHOLOGYALTERATION; MEIBOSCORE; MEIBUM SCORE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; REACTION TIME; SCHIRMER SCORE; SCORING SYSTEM; SLIT LAMP; TEAR FILM BREAK UP TIME;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DRUG THERAPY, COMBINATION; EYELID DISEASES; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; LOW TENSION GLAUCOMA; MALE; MEIBOMIAN GLANDS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; QUESTIONNAIRES; TEARS;

EID: 84867395622     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f8e7d     Document Type: Article

References (37)

1. Herreras JM, Pastor JC, Calonge M, et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088.
2. Arici MK, Arici DS, Topalkara A, et al. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol. 2000;28: 113-117.
3. Thygesen J, Aaen K, Theodorsen F, et al. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand. 2000;8:37-41.
4. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126-137.
5. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
6. Kuppens EV, Stolwijk TR, de Keizer RJ, et al. Basal tear turnover and topical timolol in glaucoma patients and healthy controls by fluorophotometry. Invest Ophthalmol Vis Sci. 1992;33:3442-3448.
7. Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol. 1979;88:739-743.
8. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87:447-450.
9. Wilson RP, Spaeth GL, Poryzees E. The place of timolol in the practice of ophthalmology. Ophthalmology. 1980;87:451-454.
10. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743-1752.
11. Sherwood MB, Grierson I, Millar L, et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucoma patients. Ophthalmology. 1989;96:327-335.
12. Brandt JD, Wittpenn JR, Katz LJ, et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991;112:297-301.
13. Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101:454-460.
14. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109-115.
15. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19:308-313.
16. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39-42.
17. Norm MS, Opauszki A. Effects of ophthalmic vehicles on the stability of the precorneal film. Acta Ophthalmol (Copenh). 1977;55:23-34.
18. Yalvaç IS, Gediko-glu G, Karagöz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246-248.
19. Kuppens EV, van Best JA, Sterk CC, et al. Decreased basal tear turnover in patients with untreated primary open-angle glaucoma. Am J Ophthalmol. 1995;120:41-46.
20. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339-342.
21. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486-490.
22. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc U K. 1985;104 (pt 4):402-409.
23. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619-630.
24. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94.
25. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: Executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922-1929.
26. Arita R, Itoh K, Inoue K, et al. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008;115:911-915.
27. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52:1994-2005.
28. Arita R, Itoh K, Maeda S, et al. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology. 2009;116:2058-2063.
29. Shimazaki J, Goto E, Ono M, et al. Meibomian gland dysfunction in patients with Sjogren Syndrome. Ophthalmology. 1998;105:1485-1488.
30. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
31. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003; 12:480-485.
32. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
33. Jester JV, Nicolaides N, Smith RV. Meibomian gland studies: Histologic and ultrastructural investigations. Invest Ophthalmol Vis Sci. 1981;20: 537-547.
34. Nicolaides N, Santos EC, Smith RE, et al. Meibomian gland dysfunction, III. Meibomian gland lipids. Invest Ophthalmol Vis Sci. 1989;30: 946-951.
35. Arita R, Itoh K, Maeda S, et al. Meibomian gland duct distortion in patients with perennial allergic conjunctivitis. Cornea. 2010;29: 858-860.
36. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59:667-669.
37. Pauly A, Meloni M, Brignole-Baudouin F, et al. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: Early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009;50:1644-1652.